Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Relate... (company that discovers develops and mark...)

HOME >> MEDICINE >> TECHNOLOGY

Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses

Date:8/2/2011

company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes US-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/us.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, safety, efficacy, tolerability, mechanism of action and potential of lorcaserin; the significance of the results from the human CSF clinical study of lorcaserin, including the use of the results of the clinical study in determining the human relevance of, and addressing, the observation of brain astrocytoma in male rats, in estimating the exposure of the human brain to lorcaserin, and estimating safety margin; the accuracy of estimates of safety margin based on relative brain exposure; the FDA's analysis of data and its view and acceptance of the CSF data, estimates, and Arena's assumptions, extrapolations and analysis; the response to the CRL for the lorcaserin NDA, including related plans and activities; the Eisai collaboration and potential activities thereunder; lorcaserin's patent coverage; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially fr
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:5/21/2013)... , May 21, 2013 Accuray Incorporated ... the publication of study results involving hundreds of ... Radiosurgery System, the most widely used form of ... followed 304 patients for a median of 5 ... found that 97 percent of patients with low-risk ...

(Date:5/21/2013)... Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...

(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...

Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2 New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7 Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2

[0] New Data Validates CyberKnife SBRT for Prostate Cancer Treatment [0] Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients [0] Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference

... N.J., Dec. 15 Synvista Therapeutics, Inc. (NYSE ... dosed the first patient in a 30-patient Phase 2 ... patients with psoriasis. The trial is planned to be ... assess the efficacy of topical SYI-2074, applied twice daily, ...

... DIEGO, Dec. 14 bioTheranostics, a bioMerieux company,that ... in,oncology, reported today findings from three studies using ... of disease recurrence in,individual patients. Data from the ... Breast Cancer Symposium (SABCS). , ...

Cached Medicine Technology:Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis 2 Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis 3 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 2 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 3 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 4

Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium

(Date:5/21/2013)... DISCcert has served the training industry ... 17 DISC applications at the July 25 & 26th ... The July 25 & 26th DISC certification in San ... applying DISC. The time-tested, proven support materials will include ... DISC training materials ; worksheets, handouts, learning activities, ...

(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...

(Date:5/21/2013)... Paris, France: The Orsiro stent, which is a ... polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting ... late lumen loss at nine months in the ... 2013 today. , The BIOFLOW-II substudy used intravascular ... quantitatively assess neointimal hyperplasia and stent apposition at ...

(Date:5/21/2013)... 2013 Phoseon Technology will present their ... 20th Annual IMI European Ink Jet Conference (June ... Phoseon continues to invest in product development to enable ... UV LED curing in printing applications. Phoseon currently ... market offering both air cooled and water cooled solutions ...

(Date:5/21/2013)... recently published in the New England Journal of ... the University of Colorado School of Medicine finds that ... be used to identify individuals at risk for this ... common variant of the gene for mucin-5B, a protein ... the bronchial tubes. While this variant of the MUC5B ...

Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3 Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2 Health News:Researchers find genetic risk factor for pulmonary fibrosis 2

[0] DISCcert Offers 17 Applications in Coming DISC Certification [0] Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants [0] Biodegradable stent proves non-inferior to drug-eluting stent [0] Phoseon Technology Presents the Leading UV LED Curing Solutions at IMI European Ink Jet Conference [0] Researchers find genetic risk factor for pulmonary fibrosis

... ... ... ... ...

... ... motorist and developed tinnitus, or severe ringing in her ears; she was granted compensation for ... ... carrier represented by East Tennessee attorney Brack Terry of Terry, Terry & Stapleton ...

... ... than £200 this month because of the cold snap. After one of the coldest Januarys in ... £226 – a £70 hike. , ... February 19, 2010 -- Britons are facing record energy bills of more than £200 this month ...

... Contrast-enhanced magnetic resonance imaging (MRI) may help physicians differentiate ... and wrist enabling more targeted therapies unique to each ... of the American Journal of Roentgenology . Contrast-enhanced ... internal bodily structures. Rheumatoid ...

... ... ... ... ...

MDS Announces Substantial Issuer Bid East Tennessee Attorney Brack Terry Obtains $120,000 Jury Award For Injured Mail Carrier It's Snow Joke as UK Gas and Electricity Bills Hit Record Highs -- Energyhelpline Calls for “Significant” Price Cuts Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis FDA Cancer Drug Approval Rate Highlighted in JNCI 'The Dance' Fundraising Event on February 25th Will Feature Belladiva Show Band; Silent Auction Items Include a Two-Week Condo Stay in New Zealand

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Chlamydia pneumoniae Antibodies, IgG & IgM by ELISA Chlamydia Group Antibody, Screen Chimerism, Recipient Pre-Transplant Chenodeoxycholic Acid